With a global, confirmatory phase III trial under way as of June with Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF), plus a phase III experiment in nonsense mutation Duchenne muscular dystrophy (nmDMD) fully enrolled as of last month, PTC Therapeutics Inc. is raising $108.75 million through the sale of 3 million shares at $36.25 each.